GlaxoSmithKline plc Company Profile (LON:GSK)

About GlaxoSmithKline plc

GlaxoSmithKline plc logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $19.82
  • 50 Day Moving Average: $1652.95
  • 200 Day Moving Average: $1575.94
  • 52-Week Range: GBX 1,277.25 - GBX 1,745.56
  • Trailing P/E Ratio: 2710.83
  • P/E Growth: 1.10
  • Market Cap: $79.06B
  • Outstanding Shares: 4,861,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (LON:GSK) (?)
Ratings Breakdown: 3 Sell Ratings, 15 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: GBX 1,690.48

Analysts' Ratings History for GlaxoSmithKline plc (LON:GSK)
DateFirmActionRatingPrice TargetDetails
10/25/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details
10/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
10/21/2016Credit Suisse Group AGBoost Price TargetNeutralGBX 1,440 -> GBX 1,800View Rating Details
10/20/2016InvestecInitiated CoverageBuyGBX 1,925View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,834View Rating Details
10/19/2016Goldman Sachs Group Inc.Set Price TargetBuyGBX 1,800View Rating Details
10/17/2016Bryan, Garnier & CoReiterated RatingBuyView Rating Details
10/13/2016Jefferies GroupBoost Price TargetBuyGBX 1,900 -> GBX 1,950View Rating Details
10/12/2016Deutsche Bank AGReiterated RatingHoldGBX 1,870View Rating Details
10/5/2016Citigroup Inc.Reiterated RatingBuyGBX 1,800View Rating Details
9/30/2016BNP ParibasReiterated RatingUnderperformGBX 1,520View Rating Details
9/20/2016Liberum CapitalReiterated RatingBuyGBX 1,900View Rating Details
9/14/2016Societe GeneraleReiterated RatingSellGBX 1,320View Rating Details
9/12/2016HSBCReiterated RatingBuyGBX 1,970View Rating Details
9/5/2016Shore CapitalReiterated RatingHoldView Rating Details
8/9/2016Berenberg BankSet Price TargetNeutralGBX 1,885View Rating Details
8/4/2016Independent Research GmbHSet Price TargetNeutralGBX 1,800View Rating Details
7/27/2016S&P Global Inc.Set Price TargetNeutralGBX 1,650View Rating Details
7/11/2016Morgan StanleyBoost Price TargetEqual weightGBX 1,500 -> GBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
5/4/2016Barclays PLCBoost Price TargetOverweightGBX 1,650 -> GBX 1,670View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
1/13/2016NatixisReiterated RatingNeutralGBX 1,470View Rating Details
11/17/2015JP Morgan CazenoveReiterated RatingNeutralGBX 1,370View Rating Details
11/6/2015Oddo SecuritiesReiterated RatingReduceGBX 1,360View Rating Details
10/5/2015Kepler Capital MarketsReiterated RatingHoldGBX 1,540View Rating Details
9/7/2015Bank of America Corp.UpgradeNeutralView Rating Details
6/9/2015Cenkos Securities LtdReiterated RatingBuyGBX 1,643View Rating Details
5/7/2015Charles StanleyReiterated RatingaccumulateView Rating Details
(Data available from 10/26/2014 forward)


Earnings History for GlaxoSmithKline plc (LON:GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2016$29.41N/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline plc (LON:GSK)
Current Year EPS Consensus Estimate: $98.33 EPS


Dividend History for GlaxoSmithKline plc (LON:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline plc (LON:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)


Latest Headlines for GlaxoSmithKline plc (LON:GSK)
DateHeadline logo[$$] GlaxoSmithKline lays plans to secure post-Brexit supply chain (LON:GSK) - October 26 at 5:23 PM logoGlaxoSmithKline plc (ADR) (GSK) Seeks FDA Approval for New Shingles Vaccine (LON:GSK) - October 24 at 12:55 PM logo[$$] The FT looks ahead to the week's main events (LON:GSK) - October 23 at 9:48 AM logoAnalysts EPS Target At $0.77 For GlaxoSmithKline PLC (NYSE:GSK) - Stocks Daily (LON:GSK) - October 22 at 5:02 PM logoA solid, defensive play for yield investors, but just what could sink GSK? (LON:GSK) - October 19 at 10:13 AM logoGlaxoSmithKline : *BERNSTEIN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1834 PENCE -'MARKET-PERFORM' (LON:GSK) - October 19 at 10:13 AM logoDirector Deals - GlaxoSmithKline PLC (GSK) (LON:GSK) - October 18 at 10:20 AM logoGlaxoSmithKline Plc (NYSE:GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App (LON:GSK) - October 18 at 10:20 AM logoMore predictions of a British slowdown but here’s what you can do (LON:GSK) - October 18 at 10:20 AM
News IconMarket Traders Recap - GlaxoSmithKline plc's (GSK) - Hot Stocks Point (LON:GSK) - October 16 at 9:54 AM logoGlaxoSmithKline : Federal Contracts Awarded to Companies in North Carolina (Oct. 15) (LON:GSK) - October 15 at 5:03 PM logo[$$] A better path to the top for women makes sense (LON:GSK) - October 14 at 5:13 PM logo[$$] A better path to the top for women makes sense (LON:GSK) - October 14 at 5:13 PM
News IconHigh Market Cap Stock of the Day – GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) - October 13 at 5:22 PM
News IconUpcoming Earnings Report: GlaxoSmithKline plc (NYSE:GSK) - The Voice Registrar (LON:GSK) - October 12 at 5:21 PM logoGlaxoSmithKline : ACCC finalises investigation into GlaxoSmithKline's pricing claims (LON:GSK) - October 10 at 9:58 AM
News IconDrug Manufacturers – Major: GlaxoSmithKline plc (NYSE:GSK) Position of the day (LON:GSK) - October 10 at 9:58 AM logoNew data published for GSK’s Nucala investigating hospitalisation reduction in severe asthma patients with an eosinophilic phenotype (LON:GSK) - October 7 at 10:16 AM
News IconGSK completes divestment of drinks, distribution business (LON:GSK) - October 5 at 10:31 AM
News IconGSK Nigeria Completes Divestment of Drinks Bottling Business (LON:GSK) - October 5 at 10:31 AM
News IconGSK Consumer Nigeria Plc Announces the Completion of Its Divestment (LON:GSK) - October 4 at 5:10 PM logoGlaxoSmithKline Plc (NYSE:GSK) Settles China Bribery Charges With $20M (LON:GSK) - October 4 at 5:10 PM logoGlaxoSmithKline Plc breached its 50 day moving average in a Bullish Manner : GSK-GB : October 4, 2016 (LON:GSK) - October 4 at 10:07 AM logoAre dividends set to soar at these FTSE 100 favourites? (LON:GSK) - October 4 at 10:07 AM logoZika vaccine race spurred by crisis and profit potential (LON:GSK) - October 4 at 10:07 AM
News IconActive Eye Catching Stocks- GlaxoSmithKline plc (NYSE:GSK ... - Seneca Globe (LON:GSK) - October 3 at 5:05 PM
News IconDoes This Dividend Darling Have Any Upside: GlaxoSmithKline plc (NYSE:GSK) - CSZ News (LON:GSK) - October 3 at 5:05 PM
News IconGSK Nigeria completes sale of drinks business, transfers ownership to Suntory (LON:GSK) - October 2 at 4:46 PM
News IconGlaxoSmithKline to pay $20 million to settle US foreign bribery case (LON:GSK) - October 2 at 4:46 PM
News IconGlaxo paying $20M to resolve SEC charges of China bribery + SEC case summary (LON:GSK) - October 1 at 4:51 PM
News IconLooking at This Dividend Stock With Upside Possibility: GlaxoSmithKline plc (NYSE:GSK) - Post News (LON:GSK) - September 30 at 5:36 PM
News IconGSK, Ashaka Cement, Fidson Emerge Top Market Losers (LON:GSK) - September 30 at 10:28 AM logoGSK Launches Horlicks Growth+ (LON:GSK) - September 28 at 10:11 AM
News IconJob at GlaxoSmithKline Plc for an Africa/DC CEP Market Lead (LON:GSK) - September 28 at 10:11 AM logoInteresting GSK Put And Call Options For November 4th (LON:GSK) - September 22 at 12:25 PM logoWhat GlaxoSmithKline plc’s choice of CEO means for shareholders (LON:GSK) - September 22 at 8:24 AM logoGlaxoSmithKline's choice of new boss disappoints City (LON:GSK) - September 21 at 3:32 PM
News IconLeading stocks in today’s market: GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) - September 21 at 3:32 PM logo[$$] GlaxoSmithKline Names Emma Walmsley as Next Chief Executive (LON:GSK) - September 21 at 9:33 AM logoInside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic (LON:GSK) - September 21 at 9:33 AM logoIs Sinclair Pharma plc a better bet than GlaxoSmithKline plc? (LON:GSK) - September 21 at 9:33 AM logo[$$] GlaxoSmithKline Names Emma Walmsley as Next CEO (LON:GSK) - September 20 at 10:26 AM
News IconGlaxoSmithKline plc (GSK) Given Buy Rating at Beaufort Securities ... - DailyQuint (LON:GSK) - September 19 at 5:25 PM logoInteresting GSK Put And Call Options For May 2017 (LON:GSK) - September 19 at 12:27 PM
News IconGSK sells anaesthesia portfolio to Aspen (LON:GSK) - September 19 at 9:54 AM logoGlaxoSmithKline : GSK cuts vaccine price for refugees, bowing to pressure (LON:GSK) - September 19 at 9:54 AM logoGlaxoSmithKline : GSK closes UK factory due to flooding (LON:GSK) - September 16 at 5:11 PM
News IconLiberum Capital Indicates Potential 17.87% Increase In Shares Of GlaxoSmithKline PLC (LON:GSK) - September 16 at 5:11 PM logoGlaxoSmithKline plc (NYSE:GSK) (GSK), Johnson & Johnson (NYSE:JNJ) Submit Subcutaneous Sirukumab MAA To ... - Market Exclusive (LON:GSK) - September 15 at 8:24 AM logoGlaxoSmithKline : *RPT/EXANE CUTS GLAXOSMITHKLINE TO 'UNDERPERFORM' (NEUTRAL) (LON:GSK) - September 14 at 5:25 PM


Last Updated on 10/26/2016 by Staff